ABC Heart Fail Cardiomyop 2021; 1(2): 130-131

Genetic Testing in Amyloidosis: For Whom?

Paulo Vinicius Ramos Souza, Fabio Fernandes, Felix José Alvarez Ramires

DOI: 10.36660/abchf.20210025

Over the past years, the recognition of cardiac involvement due to deposition of amyloid substances has received greater emphasis. Cardiac amyloidosis (CA), as it is known, has been shown to be a more prevalent cause of heart failure with preserved ejection fraction than in previous decades, although diagnosis remains a constant challenge.

With advances in pathophysiological knowledge of this disease, as well as relevant advances in diagnostic methods, particularly in the field of cardiovascular imaging, there has been a significant contribution to earlier identification of CA, as well as a consistent change in the natural course of the disease, given that we are witnessing the emergence of therapies that are capable of prolonging these patients’ survival.

[…]